Generic Sterile Injectable Ecosystem Market Size, Share, Growth Report 2030

Generic Sterile Injectable Ecosystem Market

Generic Sterile Injectable Ecosystem Market By Drug Type (Antibiotics, Blood Clotting Factors, Cytokines, Immunoglobulin, Insulin, Monoclonal Antibodies, Peptide Hormones, Vaccines, Others), By Therapeutic Application (Cancer, Cardiovascular Disease (CVD), Central Nervous System, Diabetes, Musculoskeletal System, Others), By Distribution Channel (Drug Stores, Hospitals, Retail Pharmacies), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2023 – 2030

Category: Healthcare Report Format : PDF Pages: 197 Report Code: ZMR-5626 Published Date: Mar-2023 Status : Published

The global generic sterile injectable ecosystem market size was $240.42 Billion in 2022 and is predicted to reach $570.23 Billion by 2030, increasing at 10.6%.

Generic Sterile Injectable Ecosystem Market

Industry Perspective:

The generic sterile injectable ecosystem market size is set for rapid growth over the forecast period. In terms of revenue, the global generic sterile injectable ecosystem market accounted for USD 240.42 Billion in 2022 and is expected to reach USD 570.23 Billion by 2030, growing at a CAGR of 10.6% during the forecast period.

Global Generic Sterile Injectable Ecosystem Market SizeRequest Free Sample

Generic Sterile Injectable Ecosystem Market: Overview

The generic sterile injectable refers to the biologics used in the treatment of a variety of medications which includes the same active ingredients that are present in the branded versions. Its inactive contents can, however, differ from one another. The generic sterile injectable production method is governed by the U.S. Administration of Food and Administration (FDA) and is the same as its marketed counterparts. According to the U.S. National Center for Health Statistics, when the illness lasts for more than three months within the patient it is considered a chronic disease. Such diseases are marked as one of the major causes of death as they cannot be easily cured by vaccines and other medications.

In 2015, non-communicable chronic diseases accounted for over 38 million deaths worldwide, according to the World Health Organization (WHO). Diabetes, arthritis, asthma, cancer, cardiovascular diseases, and even viral disorders such as Hepatitis or HIV/AIDS are among these diseases. In addition, according to the 2013 factsheet of the Centers for Disease Control and Prevention (CDC), arthritis was the most common cause of disability with 22 million patients diagnosed in the U.S. Due to arthritis, these patients faced obstruction in physical activity. It is also studied that nearly 47 percent of the U.S. population have at least a significant risk factor for cardiovascular disease, majorly due to smoking habits, high blood pressure, and uncontrolled low-density lipoproteins cholesterol. Increasing number of these diseases are anticipated to drive the market growth.

Key Insights

  • As per the analysis shared by our research analyst, the global generic sterile injectable ecosystem market is expected to grow annually at a promising CAGR of around 10.6% during the forecast period 2023-2030.
  • In terms of revenue, the global generic sterile injectable ecosystem market size was valued at around USD 240.42 billion in 2022 and is expected to reach USD 570.23 billion by 2030.
  • The generic sterile injectable ecosystem refers to the network of manufacturers, suppliers, distributors, and other stakeholders involved in the development, production, and distribution of generic sterile injectable drugs. Sterile injectable drugs, needles and syringes, pharmaceutical products that are administered directly into the bloodstream or other parts of the body using .
  • Based on drug type, the vaccines segment held the largest market share in 2022.
  • Based on distribution channel, the hospital pharmacies segment held the dominating market share in 2022.
  • Based on region, the North American region held the largest market share in 2022.

Global Generic Sterile Injectable Ecosystem MarketRequest Free Sample

Generic Sterile Injectable Ecosystem Market: Growth Factors

Increase in number of chronic diseases among people drives the growth of the market

Growing number of chronic diseases especially cancer across the globe is predicted to boost the demand for the generic sterile injectable ecosystem market over the forecast period. Moreover, the growth of the target market is also being propelled by a rising number of drug manufacturers focused on the development of cancer drugs. In addition, rapid FDA approvals of sterile injectable drugs in combination with shortened approval times for new drug production in cancer cure are increasing the availability of drugs and eventually fueling demand in the global market for generic sterile injectables.

The demand is expected to be powered by a variety of favorable factors over the next couple of years. Because of the sedentary lifestyles, aging population, and unhealthy eating habits, cases of chronic diseases have been increasing. This has contributed to a greater demand for the generic sterile injectables ecosystem. Furthermore, the country's drug shortages coupled with swift U.S. FDA approvals are expected to improve the production of these medicines. The patent expiry of a large number of marketed injectable drugs is also estimated to help the growth of the industry.

Generic Sterile Injectable Ecosystem Market: Restraints

Limited availability of drugs and inadequate healthcare infrastructure are predicted to impede the market growth

A significant restraint is the limited availability of these drugs in some parts of the world. This is due to several factors such as inadequate healthcare infrastructure, limited access to advanced technologies, and regulatory challenges in certain regions. Furthermore, the generic sterile injectable ecosystem market is also impacted by the increasing competition from established players, as well as the emergence of new entrants in the market. This may lead to pricing pressure and reduced profit margins for market players. These factors impede the growth of the market during the forecast period.

Generic Sterile Injectable Ecosystem Market: Opportunities

Adoption of advanced technologies and an increase in investment in healthcare creates ample opportunities for the market

One of the significant opportunities is the increasing demand for cost-effective and efficient drug delivery systems, particularly in emerging markets. The rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases also presents a significant opportunity for the market. The increasing adoption of advanced technologies such as autoinjectors, prefilled syringes, and wearable injectors is another potential opportunity for generic sterile injectable ecosystem industry growth. Moreover, the emergence of biosimilars, the expansion of the healthcare industry, and the growing focus on value-based care also provide significant opportunities for the market to expand its presence globally.

Generic Sterile Injectable Ecosystem Market: Challenges

Prevalence of pricing pressure and shortage of raw materials act as a challenge for the market

The generic sterile injectable ecosystem market faces various challenges across the world, including regulatory hurdles, pricing pressure, and competition from established and new players. Additionally, the market may also face challenges related to shortages of raw materials and skilled labor, as well as disruptions in the supply chain. These factors might create formidable challenges for the growth of the market during the forecast period.

Generic Sterile Injectable Ecosystem Market: Segmentation

The global generic sterile injectable ecosystem market is segmented based on drug type, therapeutic application, distribution channel, and region.

Based on drug type, the market is bifurcated into antibiotics, blood clotting factors, cytokines, immunoglobulin, insulin, monoclonal antibodies, peptide hormones, vaccines, and others. Of these, the vaccine segment held the dominating market share in 2022 and is further predicted to grow rapidly at a significant CAGR during the forecast period. The vaccine segment is expected to experience significant growth in the coming years due to the increasing focus on preventative healthcare and the development of innovative vaccines.

Moreover, the expansion of vaccination programs in emerging markets and the growing demand for combination vaccines are also expected to drive the growth of the vaccine segment. The most profitable sub-segments of the vaccine segment include the flu vaccine and the HPV vaccine. The flu vaccine is in high demand, especially during flu seasons, and several companies are investing in the development of next-generation flu vaccines. The HPV vaccine is another profitable sub-segment, driven by the increasing awareness about cervical cancer and the benefits of vaccination in preventing it. Overall, the vaccine segment presents significant opportunities for growth and expansion, driven by the increasing demand for preventive healthcare and the development of innovative vaccines.

Based on therapeutic application, the generic sterile injectable ecosystem industry is segregated into cancer, cardiovascular disease (CVD), central nervous system, diabetes, musculoskeletal system, others

Based on distribution channel, the market is divided into drug stores, hospitals, and retail pharmacies. Of these, the hospital pharmacies segment held the largest market share in 2022 and is further predicted to occupy a remarkable CAGR during the forecast period. The hospital pharmacies segment is expected to experience significant growth in the coming years, driven by the increasing number of hospital visits, the growing prevalence of chronic diseases, and the expansion of healthcare facilities. Moreover, the trend towards value-based care and the increasing emphasis on patient safety are expected to drive the growth of the hospital pharmacies segment.

Recent Developments

  • In February 2021, Teva Pharmaceuticals, an Israeli multinational pharmaceutical company, announced the launch of a generic version of Abraxane (paclitaxel protein-bound particles for injectable suspension), a chemotherapy drug used to treat breast cancer and non-small cell lung cancer. This launch is expected to provide a cost-effective treatment option for cancer patients.
  • In December 2020, Hikma Pharmaceuticals, British multinational pharmaceutical company, announced the launch of a generic version of Foscavir (foscarnet sodium injection), an antiviral drug used to treat cytomegalovirus infections. The launch is expected to provide a more affordable treatment option for patients with compromised immune systems.

Generic Sterile Injectable Ecosystem Market: Report Scope

Report Attributes Report Details
Report Name Generic Sterile Injectable Ecosystem Market Research Report
Market Size in 2022 USD 240.42 Billion
Market Forecast in 2030 USD 570.23 Billion
Growth Rate CAGR of 10.6%
Number of Pages 197
Key Companies Covered Aspen Pharmacare Holding, Ltd., AuroMedics Pharma LLC, Cipla Pharmaceuticals, Inc., CSC Pharmaceuticals, Inc., Fresenius Kabi, Kay Pharma, Lupin Limited, Reddys Laboratories Limited, Sun Pharmaceutical Industries, Ltd., and Valeant Pharmaceuticals, Inc. among others.
Segments Covered By Drug Type, By Therapeutic Application , By Distribution Channel, And By Region
Regions Covered North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA)
Base Year 2022
Historical Year 2017 to 2021
Forecast Year 2023 - 2030
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Generic Sterile Injectable Ecosystem Market: Regional Analysis

North America followed by Europe to rule the global market

North America and Europe, being developed economies with a higher concentration of market players and healthcare resources, are estimated to drive the growth of the global generic sterile injectable market over the forecast period. The rising investment in research & development and advanced use of oncology-based drugs in clinics and hospitals for the treatment of different types of cancers have contributed to the growth of the market in North America. Asia Pacific is predicted to grow at the fastest rate between 2022 to 2030, as a majority of manufacturers of low-cost generic injectables are concentrating on establishing healthcare facilities in the region.

Generic Sterile Injectable Ecosystem Market: Competitive Players

Some of the key players in the global generic sterile injectable ecosystem market are:

  • Aspen Pharmacare Holding Ltd.
  • AuroMedics Pharma LLC
  • Cipla Pharmaceuticals Inc.
  • CSC Pharmaceuticals Inc.
  • Fresenius Kabi
  • Kay Pharma
  • Lupin Limited
  • Reddys Laboratories Limited
  • Sun Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals Inc.

The global generic sterile injectable ecosystem market is segmented as follows:

By Drug Type

  • Antibiotics
  • Blood Clotting Factors
  • Cytokines
  • Immunoglobulin
  • Insulin
  • Monoclonal Antibodies
  • Peptide Hormones
  • Vaccines

By Therapeutic Application

  • Cancer
  • Cardiovascular Disease (CVD)
  • Central Nervous System
  • Diabetes
  • Musculoskeletal System

By Distribution Channel

  • Drug Stores
  • Hospitals
  • Retail Pharmacies

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

The generic sterile injectable refers to the biologics used in the treatment of a variety of medications which includes the same active ingredients that are present in the branded versions. Its inactive contents can, however, differ from one another. The generic sterile injectable production method is governed by the U.S. Administration of Food and Administration (FDA) and is the same as its marketed counterparts. According to the U.S. National Center for Health Statistics, when the illness lasts for more than three months within the patient it is considered a chronic disease. Such diseases are marked as one of the major causes of death as they cannot be easily cured by vaccines and other medications.

The global generic sterile injectable ecosystem market is predicted to increase at a CAGR of 10.6% during the forecast period.

The global generic sterile injectable ecosystem market was worth around USD 240.42 billion in 2022 and is expected to reach USD 570.23 billion by 2030.

The global market for the generic sterile injectable ecosystem is driven by persistent advancements in biotechnology, growing cases of chronic diseases among people across the globe, and the ease of sterile injectables in medical treatment drives the growth of the market.

North America held the largest share in the global generic sterile injectable ecosystem market in 2022 and is likely to continue the same trend during the forecast period. The generic sterile injectable ecosystem market in North America is expected to grow due to various factors such as the increasing prevalence of chronic diseases, rising demand for cost-effective treatments, and the need for safe and efficient drug delivery systems.

Some of the major companies operating in the generic sterile injectable ecosystem market include Aspen Pharmacare Holding, Ltd., AuroMedics Pharma LLC, Teva Pharmaceuticals, Hikma Pharmaceuticals, Pfizer, Bayer, Sanofi, Roche, Merck, Sandoz, Mylan, Hospira, ABBVie, Novartis, Cipla Pharmaceuticals, Inc., CSC Pharmaceuticals, Inc., Fresenius Kabi, Kay Pharma, Lupin Limited, Reddys Laboratories Limited, Sun Pharmaceutical Industries, Ltd., and Valeant Pharmaceuticals, Inc. among others.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed